SME Times is powered by   
Search News
Just in:   • Equity indices break two-day losing streak on value buying  • IMF urges Sri Lanka to tighten monetary policy  • Global semiconductor sales to reach $676 bn this year: Gartner  • Tinna Rubber hits upper circuit, investors accumulate 900% returns in year  • Availability of jobs in Japan improves for 1st time in 3 yrs 
Last updated: 23 Jan, 2022  

Tablet.9.Thmb.jpg Fewer launches subdue pharma market's Dec sequential growth

   Top Stories
» Net direct tax collection reaches highest-ever figure in FY 22
» Musk has to manufacture here to sell Tesla cars in India: Gadkari
» Round tripping of industrial inputs by large players unfavourable to local value chains
» Sitharaman engages investors in Silicon Valley
» Modi hails India's success in achieving target of $400 billion of exports
SME Times News Bureau | 23 Jan, 2022
Lower volumes along with fewer number of new launches subdued Indian Pharmaceutical Market (IPM) growth during December 2021 on a sequential basis.

As per India Ratings and Research (Ind-Ra), IPM continued to deliver slower growth of 5.3 per cent YoY in December 2021 after growing 6.6 per cent in November 2021.

"The acute therapy segment performed in line with sub-chronic and chronic segments in December 2021," the ratings agency said.

Accordingly, Ind-Ra highlighted that acute segment has been showing a robust performance since March 2021.

"Post normalisation of the high growth months of April 2021 and May 2021 led by the lockdown related lower base last year and higher volume growth, the average IPM growth from June to December 2021 has been healthy.

"In terms of growth drivers, th price growth, new product launches growth and volume growth stood at 5.6 per cent, 2.9 per cent and 6.4 per cent YoY, respectively, during moving annual total, which led to an overall IPM size of Rs 1,671 billion in December 2021," it said.

According to the agency, the acute therapy segment reported sales growth of 5.3 per cent YoY, while chronic and sub-chronic therapy segments reported growth at 4.8 per cent and 6 per cent, respectively, in December 2021.

"During FY21, Ind-Ra highlights that the acute therapy segment reported negative growth on account of Covid-19 while the chronic therapy segment reported average growth of 7 per cent in the same period."
Print the Page
Add to Favorite
Share this on :

Please comment on this story:
Subject :
(Maximum 1500 characters)  Characters left 1500
Your name:

  Customs Exchange Rates
Currency Import Export
US Dollar
UK Pound
Japanese Yen 58.85 56.85
As on 27 Apr, 2022
  Daily Poll
COVID-19 has directly affected your business
 Can't say
  Commented Stories
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter